The surface antigenicity of serially transplantable malignant human lymphoid cells derived from subjects with infectious mononucleosis, Hodgkin's disease, chronic lymphatic leukemia, or acute lymphoblastic leukemia.
D000818:Animals; D000941:Antigens; D000951:Antigens, Neoplasm; D002462:Cell Membrane / Q000276:immunology*; D006224:Cricetinae; D005455:Fluorescent Antibody Technique; D006689:Hodgkin Disease / Q000276:immunology*; D006801:Humans; D007106:Immune Sera; D007136:Immunoglobulins / Q000032:analysis; D007165:Immunosuppression Therapy; D007244:Infectious Mononucleosis / Q000276:immunology*; D007942:Leukemia, Experimental / Q000276:immunology*; D007945:Leukemia, Lymphoid / Q000276:immunology*; D008214:Lymphocytes / Q000276:immunology*; D008221:Lymphoid Tissue / Q000276:immunology*; D008228:Lymphoma, Non-Hodgkin / Q000150:complications; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology*; D011817:Rabbits / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014183:Transplantation, Heterologous
D000941:Antigens; D000951:Antigens, Neoplasm; D007106:Immune Sera; D007136:Immunoglobulins